Jillian A Johnson1, Sheila N Garland2,3, Linda E Carlson4,5, Josée Savard6, J Steven A Simpson5,7, Sonia Ancoli-Israel8, Tavis S Campbell9,10. 1. Department of Biobehavioral Health, College of Health and Human Development, Pennsylvania State University, University Park, PA, USA. 2. Department of Psychology, Faculty of Science, Memorial University of Newfoundland, St. John's, NL, Canada. 3. Division of Oncology, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada. 4. Department of Psychology, Faculty of Arts, University of Calgary, Calgary, AB, Canada. 5. Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 6. School of Psychology, Faculty of Social Sciences, Université Laval, Laval, QC, Canada. 7. Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 8. Departments of Psychiatry and Medicine, University of California San Diego, San Diego, CA, USA. 9. Department of Psychology, Faculty of Arts, University of Calgary, Calgary, AB, Canada. t.s.campbell@ucalgary.ca. 10. Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. t.s.campbell@ucalgary.ca.
Abstract
PURPOSE:Cancer-related fatigue (CRF) is a common and distressing symptom that can persist after cancer treatment has concluded. Bright light therapy has shown preliminary efficacy in reducing CRF, but its impact on other psychosocial factors is unclear. The purpose was to examine the impact of a 1-month light therapy intervention on fatigue, mood, and quality of life in cancer survivors with fatigue. METHODS: This 4-week blinded randomized controlled trial recruited cancer survivors who met diagnostic criteria for CRF. Participants were randomly assigned to receive a light therapy device that produced either bright white light (BWL; intervention) or dim red light (DRL; active control). Participants were instructed to use the device daily for 30 min upon waking for 28 days. The primary outcome, fatigue, was assessed weekly. Secondary outcomes assessed pre- and post-intervention included mood, depressive symptoms, and quality of life. RESULTS:A total of 81 participants were randomly assigned to receive BWL (n = 42) or DRL (n = 39). Analyses revealed a group-by-time interaction for fatigue (p = .034), wherein the BWL condition reported a 17% greater reduction in fatigue than those in the DRL condition (between group d = .30). There were also significant improvements over time for both groups on measures of mood, depressive symptoms, and quality of life (p's < .01). CONCLUSIONS: BWL was associated with greater improvements in fatigue and both groups displayed improvements on secondary psychosocial outcomes. IMPLICATIONS FOR CANCER SURVIVORS: These findings, along with previous reports of light therapy for CRF, support the use of this intervention to improve fatigue in cancer survivors.
RCT Entities:
PURPOSE:Cancer-related fatigue (CRF) is a common and distressing symptom that can persist after cancer treatment has concluded. Bright light therapy has shown preliminary efficacy in reducing CRF, but its impact on other psychosocial factors is unclear. The purpose was to examine the impact of a 1-month light therapy intervention on fatigue, mood, and quality of life in cancer survivors with fatigue. METHODS: This 4-week blinded randomized controlled trial recruited cancer survivors who met diagnostic criteria for CRF. Participants were randomly assigned to receive a light therapy device that produced either bright white light (BWL; intervention) or dim red light (DRL; active control). Participants were instructed to use the device daily for 30 min upon waking for 28 days. The primary outcome, fatigue, was assessed weekly. Secondary outcomes assessed pre- and post-intervention included mood, depressive symptoms, and quality of life. RESULTS: A total of 81 participants were randomly assigned to receive BWL (n = 42) or DRL (n = 39). Analyses revealed a group-by-time interaction for fatigue (p = .034), wherein the BWL condition reported a 17% greater reduction in fatigue than those in the DRL condition (between group d = .30). There were also significant improvements over time for both groups on measures of mood, depressive symptoms, and quality of life (p's < .01). CONCLUSIONS: BWL was associated with greater improvements in fatigue and both groups displayed improvements on secondary psychosocial outcomes. IMPLICATIONS FOR CANCER SURVIVORS: These findings, along with previous reports of light therapy for CRF, support the use of this intervention to improve fatigue in cancer survivors.
Authors: Jillian A Johnson; Sheila N Garland; Linda E Carlson; Josée Savard; J Steven A Simpson; Sonia Ancoli-Israel; Tavis S Campbell Journal: Contemp Clin Trials Date: 2016-07-06 Impact factor: 2.226
Authors: Sonia Ancoli-Israel; Michelle Rissling; Ariel Neikrug; Vera Trofimenko; Loki Natarajan; Barbara A Parker; Susan Lawton; Paul Desan; Lianqi Liu Journal: Support Care Cancer Date: 2011-06-11 Impact factor: 3.603
Authors: William H Redd; Heiddis Valdimarsdottir; Lisa M Wu; Gary Winkel; Emily E Byrne; Melba A Beltre; Elizabeth S Liebman; Tanya Erazo; Judy A Hayes; Luis Isola; Eileen Scigliano; Yeraz Meschian; Susan Lutgendorf; Sonia Ancoli-Israel Journal: Psychooncology Date: 2014-05-02 Impact factor: 3.894
Authors: Xin Shelley Wang; Fengmin Zhao; Michael J Fisch; Ann M O'Mara; David Cella; Tito R Mendoza; Charles S Cleeland Journal: Cancer Date: 2014-02-01 Impact factor: 6.860
Authors: Julienne E Bower; Kate Bak; Ann Berger; William Breitbart; Carmelita P Escalante; Patricia A Ganz; Hester Hill Schnipper; Christina Lacchetti; Jennifer A Ligibel; Gary H Lyman; Mohammed S Ogaily; William F Pirl; Paul B Jacobsen Journal: J Clin Oncol Date: 2014-04-14 Impact factor: 44.544
Authors: Valerie E Rogers; Shijun Zhu; Belinda N Mandrell; Sonia Ancoli-Israel; Lianqi Liu; Pamela S Hinds Journal: Support Care Cancer Date: 2019-07-04 Impact factor: 3.603
Authors: Ari Shechter; Jacob Julian; Karina W Davidson; Ken Cheung; Jenny Lee; Ian M Kronish Journal: Psychiatry Res Date: 2019-04-17 Impact factor: 3.222
Authors: Farrah J Mateen; Andre C Vogel; Tamara B Kaplan; Gladia C Hotan; Sara J Grundy; Kathryn B Holroyd; Natalie Manalo; Matthew Stauder; Aleksandar Videnovic Journal: J Neurol Date: 2020-04-24 Impact factor: 4.849